NASDAQ · ELEV
Elevation Oncology, Inc.
$0.37-$0.01 (-2.12%)
Elevation Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.19% below the high.
Loading market information…
NASDAQ · PIRS · USD
Stock price, earnings
Quote as of Dec 13, 2024, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Pieris Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.07% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pieris Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pieris Pharmaceuticals, Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to discovering and advancing drugs based on its proprietary Anticalin technology. These Anticalin proteins are therapeutic, low-molecular-weight molecules derived from naturally occurring human lipocalins, which are found in blood plasma and other bodily fluids. The company's pipeline includes several key drug candidates: Respiratory: PRS-060/AZD1402: A lead Anticalin candidate currently in Phase II clinical trials, targeting IL-4Ra for the treatment of asthma and various inflammatory diseases. PRS-220: An orally inhaled Anticalin protein designed to target connective tissue growth factor, intended for the treatment of idiopathic pulmonary fibrosis (IPF). Immuno-Oncology: Cinrebafusp alfa: A bispecific drug targeting both 4-1BB and HER2, developed for gastric cancers that express high or low levels of HER2. PRS-344/S095012: A bispecific Anticalin-antibody fusion protein in Phase I clinical trials, targeting 4-1BB and PD-L1 for various immuno-oncology indications. PRS-352: A preclinical-stage program focusing on undisclosed targets within immuno-oncology. Pieris has established several strategic partnerships, including collaboration and licensing agreements with Les Laboratoires Servier (and Institut de Recherches Internationales Servier), AstraZeneca AB, and Seagen Inc. Further licensing agreements are in place with the Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Additionally, the company has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Established in 2000, Pieris Pharmaceuticals, Inc. maintains its headquarters in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:42 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2023 | Nov 14, 2023 | -$8.800.0% vs estimate | $19.52M+771.43% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.37-$0.01 (-2.12%)
Elevation Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.19% below the high.
$3.07+$0.29 (+10.43%)
MEI Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.89% below the high.
$3.10-$0.17 (-5.2%)
PHAXIAM Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 76.15% below the high.
$1.30+$0.11 (+9.24%)
MetaVia Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.25% below the high.
$0.57-$0.26 (-30.77%)
Kineta, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.34% below the high.
CA$9.00+CA$0.20 (+2.27%)
COSCIENS Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.27% below the high.
$0.31+$0.01 (+2.66%)
Traws Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.43% below the high.
$0.85+$0.01 (+1.44%)
Imunon, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.91% below the high.
